Clinical Trial Details
| Trial ID: | L1140 |
| Source ID: | NCT01238796 |
| Associated Drug: | Telavancin |
| Title: | A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Kidney Diseases|End Stage Renal Disease |
| Interventions: | DRUG: telavancin |
| Outcome Measures: | Primary: Concentration of telavancin as estimated by antibiotic potency bioassay, Days 1-4|Concentration of telavancin as determined by standard Liquid Chromatography Tandem Mass Spectrometer (LC/MS/MS), Days 1-4 | Secondary: Pharmacokinetic variables through analysis of blood samples, Days 1-4 |
| Sponsor/Collaborators: | Sponsor: Cumberland Pharmaceuticals |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 45 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER |
| Start Date: | 2010-12 |
| Completion Date: | 2011-02 |
| Results First Posted: | |
| Last Update Posted: | 2019-01-15 |
| Locations: | Clinical Pharmacology of Miami, Miami, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States |
| URL: | https://clinicaltrials.gov/show/NCT01238796 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|